SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neuroscience -- Ignore unavailable to you. Want to Upgrade?


To: scott_jiminez who wrote (80)9/29/2000 7:25:43 AM
From: Jim Oravetz  Read Replies (1) | Respond to of 278
 
ROCKVILLE, Md.-(BW)-Sept. 28-Panacea Pharmaceuticals, Inc. announced today that a scientific paper has been published outlining the Company's proprietary approach to treating Parkinson's Disease (PD) and other Lewy body disorders.
Panacea has exclusive worldwide rights to the technology, and the Company has established a Collaborative Research agreement with researchers at Loyola University Medical Center in Maywood, Illinois for its further development.
The findings were published in The Journal of Neuroscience (Vol. 20, No. 16, pages 6048-6054), the official journal of the Society of Neuroscience. The paper is entitled "The A53T alpha-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity." The senior author of the paper is Benjamin Wolozin, M.D., Ph.D., Panacea's collaborator at Loyola.
The data supports the theory that alpha-synuclein (A-Syn) acts in concert with iron and dopamine to induce formation of Lewy body pathology in PD and cell death in PD. The paper also describes the drug screening models that were employed by the Company leading to its two pre-clinical candidates, PAN-408 and PAN-527.

Background on Alpha-Synuclein

The discovery of the A-Syn gene has opened exciting new opportunities to explore the pathophysiology of PD and other Lewy body diseases. Lewy bodies are neuronal inclusions that are the neuropathologic hallmark of PD. A-Syn is present in Lewy bodies in PD and diffuse Lewy body disease.
In addition, mutations in A-Syn cause rare cases of familial PD, which demonstrates that changes in A-Syn biology are sufficient to drive the pathophysiology of PD.
The striking accumulation of A-Syn inclusions in Lewy body diseases indicates that A-Syn also plays an important role in the pathophysiology of these diseases.
Nevertheless, the cause of A-Syn aggregation and the role of this aggregation in causing dementia, including that seen in Alzheimer's disease, has to date been unidentified.
The paper demonstrated that iron and free radical generators stimulate the production of intracellular aggregates that contain A-Syn and ubiquitin. The amount of aggregation that occurred in the cultured neuronal cells depended on the amount and type of A-Syn expressed.
In addition to stimulating aggregate formation, A-Syn also appeared to induce toxicity, demonstrated by the observation that neuroblastoma cells overexpressing A-Syn displayed up to a fourfold increase in vulnerability to toxicity when induced by iron.
"We are continuing to screen potential inhibitors of alpha-synuclein aggregation using our proprietary models," said Hossein A. Ghanbari, Ph.D., President and CEO of Panacea.
"Our hit rate has been exceptional, and we are currently pursuing the development of two of the most active compounds, PAN-408 and PAN-527. We believe our approach can effectively address the underlying cause of Parkinson's disease, not merely the symptoms."
"This technology is already attracting enormous interest in the scientific and medical communities," stated Christopher Kircher, M.D., Chairman of Panacea's Clinical Advisory Board.
"Panacea is making the move from the standard industry approach of symptomatic treatment, which is used for the management of the disease, to a specific neuroprotective disease-modifying treatment approach that has the power to change the course of the disease.
"We are currently positioning the advisory board's membership to reflect the Company's aggressive development schedule for its current pre-clinical candidates."
Parkinson's Disease is the most common motor disorder, affecting 1% of the population over 60 years of age. Among individuals older than 70 years, 1.5-2.5% have the disease. In the United States alone, 50,000 people are diagnosed with PD each year, and more than half a million are affected at any one time. With the increasing age of the world population, a substantial increase in PD is anticipated.

Jim



To: scott_jiminez who wrote (80)9/29/2000 8:48:46 AM
From: scaram(o)uche  Respond to of 278
 
Ron:

I've owned and sold KLIC three or four times in the last couple of weeks, taking a scalp of about 1/4 on each occasion. Haven't owned it longer than overnight, and own none now. Pays the rent, that sort of trade, and they're virtually a lock...... can't remember the last time that I lost money.

As always, my personal brokerage records are completely open to anyone who will (1) provide a dinner to me and the date of my choice, at a good local restaurant, for the privilege of reviewing them, and (2) verify in public, after reviewing them, that what I've said is correct.

HAVE YOU EVER BEEN ON MY CASE - about my KLIC-related behavior?

Sorry, Ron, I don't know what your KLIC-related behavior is. I've noticed your posts to the VDCC and ARIA threads, and watched you take a beating. I know that it's a widely followed and respected stock, and I've traded it at tick-by-tick reversals on days where biotech wasn't giving me much.

NBSC..... I sit here with level II all day, and, IMO, NBSC has been capped. Sorry you see something sinister in my suspicion of the sinister, but.... please don't be silly.... I have not made any "claims about the MM holding down the price of NBSC". Read the posts again. I've indicated that, IMO, someone who is executing trades through Herzog is capping the price. I've made similar observations in the past, often before BVF or another institution has taken one of their dipsy doodle chunks. If you don't want to believe that there are traders who sacrifice shares to a greater purpose, you are welcome to live in your naivety.

Baptists, Puritans..... run amok some more.

if I had the slightest inclination to review your
thousands of previous posts I ASSURE YOU I could find glaring inconsistencies and inaccuracies that could be
construed in an extremely negative fashion as well.


Go right ahead. I've labored to point them out, subsequently, when they've occurred. I invite you.

What's most most remarkable Richard is your lack of appreciation that you're jeopardizing your own *well
deserved* reputation by this focus on my behavior. I would venture to guess you have 95% - if not 100% - of the SI BT community behind you right now (refer to 'Go Rick' etc. by tommysdad and his lack of response to my question). By maintaining this dogged pursuit, what was once an effort to bring 'visibility' to my dark past becomes an obsession to 'get even' - in other words, to get me kicked off of SI once and for all. By doing this you are, in my opinion, risking everything you've developed. In short, I'll start appearing to be the 'victim' rather than you and SI.


Wo, pretty heavy. Risking everything I've developed, sort of like my personal and professional life is going to collapse around me, for having countered your antagonistic posts? I've been wondering what I should do for my next profession...... every once in awhile I long to be a bagger at a local super market. Lots of people contact. I think that I'd like that.

Ron, I have no desire to see you kicked off of SI again. I'm sorry that you returned, and it's too bad that you haven't changed, despite the rants. But, as long as you're here, I'm going to take advantage of your insights. Thanks for the scalps on KLIC.

And what about *your* ongoing spamming of NBSC or BTRN etc.

Two points..... (1) I haven't accused you of spamming, and (2) my intent is to provide insights with respect to business plans. Since the stocks that I focus on usually appreciate, a side-effect has been to provide an opportunity to profit from the insights. Pretty cool, huh?

((past performance does not assure future success, and I'm not qualified to make investment recommendations -- everyone please do own homework, blah, blah, blah))

Aurileano -- isn't that the guy who used to point to your posts at SI, from the Yahoo Ariad thread, and give you kudos? And weren't you sort of vice versaing with him? Sort of reminded me of the cross-talk between Courtney, r. Peter Dale, Fisner, Wesley et al. I thought he was your buddy? Sorry, but you've confused me.

Message 12904678
Message 12794191

Kinda like when you came on to the Ariad thread claiming its move this spring was 'pump and dump'

Please, show me/us that post. I don't remember it, and, for the mean time, I'll just make the reasonable assumption that you're cheating again. TIA.

You still want people to cower in your presence.

Off in corners, and I expect them to come out only when they have good ideas that correspond with mine.

Gotta get ready to make money today. Good luck!



To: scott_jiminez who wrote (80)9/29/2000 9:14:41 PM
From: Miljenko Zuanic  Read Replies (2) | Respond to of 278
 
<<Do you (or your shadow, Miljenko) get on my case - HAVE YOU EVER BEEN ON MY CASE - about my KLIC-related behavior?>>

“or your shadow, Miljenko”

Miljenko is for himself, from the day when he joined SI. What I post is coming from me, and only from me. While I have great respect for what Rick post on SI (together with many others biofreaks), I do not always agree or follow his or other leads. Also, and most important (more than any investment profit one can think off) Rick is primary dear friend, than anything else.

When I informed online friends that my father-in-law past away last summer (because of the luck of medicine and medical service, local hospital in Croatia) he immediate send small contribution with intention to improve this condition.

Regards the difference, example is REGN or SIBI, where in first one Rick was concern about their luck of focus on business (compared to science), while I thought that good science will one day generate business. In SIBI case, I was (after we meet at SIBI- OH in S.D.) concerned about their chemistry and was suspicious about their lead candidates. Opposite of this is Rick cautious and warning view (at that time) about ISIP and CNSI, compared to my positive statements here at SI. There are many more, but this are typical examples.

Ron, if you have something on me, BE DIRECT.

Miljenko